What is AccuGenomics?
Headquartered in Wilmington, North Carolina, AccuGenomics operates as a commercial-stage enterprise dedicated to refining the precision of molecular diagnostic workflows. The company specializes in the development of multiplexed spike-in quality control standards, a critical component for ensuring the reliability of NGS-based assays. Through its proprietary Accukits and SNAQ-SEQ internal standards, AccuGenomics addresses the industry-wide challenge of assay sensitivity, particularly in the detection of circulating tumor DNA (ctDNA) and viral pathogens such as SARS-CoV-2. By leveraging technology licensed from the University of Toledo, the firm provides essential infrastructure for biomanufacturing and clinical diagnostic laboratories, effectively reducing false positives and enhancing the overall performance of genomic sequencing applications.
How much funding has AccuGenomics raised?
AccuGenomics has raised a total of $62K across 1 funding round:
Debt
$62K
Debt (2021): $62K with participation from PPP
Key Investors in AccuGenomics
PPP
Public-Private Partnership
What's next for AccuGenomics?
With this latest infusion of capital, AccuGenomics is poised to transition into a more aggressive phase of market expansion. The strategic focus will likely center on scaling the production of its quality control standards to meet the rising demand for standardized NGS protocols in clinical settings. As the diagnostic industry continues to prioritize data integrity and regulatory compliance, AccuGenomics is strategically aligned to become a foundational partner for laboratories seeking to optimize their diagnostic throughput. Future growth initiatives will likely involve expanding the application range of their spike-in technology to encompass a broader spectrum of oncology and infectious disease diagnostics, further cementing their status as a leader in molecular quality assurance.
See full AccuGenomics company page
